Haemonetics Corporation
HAE
$81.35
$0.600.74%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -2.45% | 0.91% | 3.95% | 8.14% | 9.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.45% | 0.91% | 3.95% | 8.14% | 9.84% |
| Cost of Revenue | -12.08% | -7.58% | -0.99% | 5.35% | 6.67% |
| Gross Profit | 5.53% | 8.07% | 8.10% | 10.50% | 12.62% |
| SG&A Expenses | -1.21% | -0.75% | 1.38% | 5.95% | 9.16% |
| Depreciation & Amortization | 9.58% | 27.42% | 50.67% | 60.21% | 36.83% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.21% | -2.96% | 2.06% | 7.35% | 8.42% |
| Operating Income | 17.15% | 22.62% | 14.19% | 12.27% | 17.91% |
| Income Before Tax | 36.67% | 43.23% | 39.64% | 2.28% | -0.26% |
| Income Tax Expenses | 39.57% | 47.01% | 29.40% | 0.52% | 13.08% |
| Earnings from Continuing Operations | 35.84% | 42.17% | 42.64% | 2.76% | -3.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.84% | 42.17% | 42.64% | 2.76% | -3.48% |
| EBIT | 17.15% | 22.62% | 14.19% | 12.27% | 17.91% |
| EBITDA | 13.81% | 19.99% | 16.82% | 16.14% | 18.18% |
| EPS Basic | 41.49% | 45.80% | 44.10% | 2.55% | -4.07% |
| Normalized Basic EPS | 8.26% | 8.47% | 10.99% | 9.24% | 17.88% |
| EPS Diluted | 42.27% | 47.02% | 44.92% | 3.25% | -3.22% |
| Normalized Diluted EPS | 8.97% | 9.19% | 11.61% | 9.78% | 18.28% |
| Average Basic Shares Outstanding | -4.04% | -2.33% | -0.74% | 0.21% | 0.58% |
| Average Diluted Shares Outstanding | -4.63% | -2.97% | -1.30% | -0.27% | 0.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |